Pheochromocytoma: 3 clinical case reports
Keywords:
phaeochromocytoma, hypertension, metanephrineAbstract
Phaeochromocytomas are rare neuroendocrine tumours with a
highly variable clinical presentation, most commonly presenting
with episodes of headaches, sweating, palpitations and hypertension. The serious and potentially lethal cardiovascular complications of these tumours are due to the potent effects of secreted
catecholamines. Biochemical testing for phaechromocytoma is
indicated, not only in symptomatic patients, but also in patients
with adrenal incidentalomas or identified genetic predispositions
(multiple endocrine neoplasia type 2, Von Hippel Lindau Syndrome,
neurofibromatosis type 1).
The authors report three cases in which a biochemical diagnosis of phaeochromocytoma was made: the first refers to a 30
year-old man admitted for investigation of a right adrenal 6cm
diameter incidentaloma; the second is a 35 year-old woman
studied for secondary hypertension and the third a 59 year-old
woman, otherwise healthy, with a right supra-renal node on a
routine ultrasound exam. Imaging techniques such as CT, MRI
and functional ligands such as I123-MIBG were used to localize
the biochemically proven tumour.
After the use of appropriate preoperative treatment to block the
effects of secreted cathecolamines, laparoscopic tumour removal
was the preferred procedure.
Prognosis is excellent.
Downloads
References
Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma, J Urol 1992; 147: 1-10.
Pacak K, Linehan WM, Eisenhofer G et al. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma, Ann Intern Med 2001;134:315-329.
Anderson GH, Blakerman N et al. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively reffered patients. J Hypertens 1994;12: 609-615.
Omura M, Saito J et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27: 193-202.
Sinclair AM, Isles CG et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987;147: 1289-1293.
Platts JK, Drew PJ. Death from pheochromocytoma: lessons from a post-mortem survey. J R Coll Physicians London 1995;29: 299-306.
Lo CY, Lam KY, Wat MS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 2000;179: 212-215.
Khorram-Manesh A, Ahlman H et al. Mortality associated with pheochro-mocytoma in a large Swedish cohort. Eur J Surg Oncol 2004; 30: 556-559.
Plouin PF, Duclos JM et al. Factors associated wiyh perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001; 86: 1480-1486.
Neumann HP, Bausch B et al. Germ line mutations in non syndromic pheochromocytoma. N Engl J Med 2002;346: 1459-1466.
Maher ER, Eng C. The pressure rises: update on the genetics of pheochromocytoma. Hum Mol Genet 2002;11: 2347-2354.
O’Riordain DS, Young WF et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 1996;20: 916-921.
Neumann HP, Berger DP et el. Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel Lindau disease. N Engl J Med 1993;329: 1531-1538.
Manger WM, Gilford RW. Clinical and experimental pheochromocytoma. Second ed. Cambridge: Blackwell Sciences, 1996.
Manelli M, Ianni L et al. Pheochromocytoma in Italy : a multicentric retrospective study. Eur J Endocrinol 1999;141: 619-624.
Bravo El, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003;24: 539-553.
Plouin PF, Degoulet P et al. Screening for pheochromocytoma in wich hypertensive patients? A semiological study of 2585 patients, including 11 with pheochromocytoma. Nouv Presse Med 1981;10: 869-872.
Batide-Alanore A, Chatellier G et al. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003;21: 1703-1707.
Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment and follow-up. Surg Oncol Clin N Am1998;7: 765-789.
Mantero F, Terzolo M et al. A Survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85: 637-644.
Bryant J, Farmer J et al. Pheochromocytoma : the expanding genetic differential diagnosis. J Natl Cancer Inst 2003;95 : 1196-1204.
Baguet JP, Hammer L et al. Circumstances of discovery of pheochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004;150: 681-686.
Mansmann G, Lau J et al. The clinical inapparent adrenal mass : update in diagnosis and managment. Endocrin Rev 2004;25: 309-340.
Amar L, Servais A et al.Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90: 2110-2116.
Sheps SG, Jiang NS et al. Diagnostic evaluation of pheochromocytoma. Endocrinol Metab Clin North Am 1998;17: 397-414.
Pacak K, Chrousos GP et al. Pheochromocytoma. Progress in diagnosis, treatment and genetics. In: Margioris AN, Chrousos GP, eds. 1st edn. Totowa, NJ,USA: Humana Press 2001:79-413.
Lenders Jacques W M, Eisenhofer G et al. Pheochromocytoma. Lancet 2005;366: 665-675.
Kudva Yogish C, Sawka Anna M et al. The Laboratory Diagnosis of Adrenal Pheochromocytoma: The Mayo Clinic Experience. J Clin Endocrinol Metab 2003;88(10): 4533-4539.
Ioannis I, Pacak K. Clinical problem solving: Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. J Clin Endocrinol Metab 2004;89(2): 479-491.
Kinney MA, Warner ME, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma ressection. Anesth Analg 2000;91: 1118-1123.
Quezado ZN, Keiser HR, et al. Reversible myocardial depression after massive catecholamine release from a pheochromocytoma. Crit Care Med 1992;20: 549-551.
Kobayashi T, Iwai A et al. Spontaneous rupture of adrenal pheochromocytoma: review and analysis of prognostic factors. J Surg Oncol 2005;90: 31-35.
Tauzin-Fin P, Sesay M et al. Effects of perioperative alpha 1 block on haemodynamic control during laparoscopic surgery for pheochromocytoma. Br J Anaesth 2004;92: 512-517.
Prys-Roberts C. Pheochromocytoma-recent progress in its managment. Br J Anaesth 2000;85: 44-57.
Lebuffe G, Dosseh ED, et al. The effect of calcium channel blockers on outcome following the surgical treatment of pheochromocytomas and para-gangliomas. Anaesthesia 2005;60: 439-444.
Steinsapir J, Carr AA et al. Metyrosine and pheochromocytoma. Arch Intern Med 1997;157: 901-906.
Kinney MA, Narr BJ et al. Perioperative managment of pheochromocytoma. J Cardiothorac Vasc Anesth 2002;16: 359-369.
Roizen MF, Schreider BD et al. Anesthesia for patients with pheochromocytoma. Anesthesiol Clin North Am 1987 ;5 : 269-275.
Janetschek G, Finkenstedt G et al. Laparoscopic Surgery for Pheochromocytoma: adrenalectomy, partial ressection, excision of paragangliomas. J Urol 1998; 160:330-334.
Eisenhofer G, Bornstein SR et al. Malignant Pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-436
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
